WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

EFFICACY AND SAFETY OF IVABRADINE IN PATIENTS WITH CHRONIC STABLE HEART FAILURE

Elavarasi P.*, Ezhil Ramya J. and Vasanth S.

ABSTRACT

INTRODUCTION: Chronic heart failure is associated with increasing incidence of mortality and morbidity. Unlike western countries where heart failure is a disease of elderly, in India it affects younger age group. The lifetime risk of developing HF at the age of 40 yr is 11.4 % for men and 15.4 % for women. Ivabradine is a novel specific and selective heart rate lowering agent that acts in sino-atrial node cells by selectively inhibiting the cardiac pacemaker in a dose dependant manner. OBJECTIVE: To evaluate the efficacy and safety of Ivabradine in patients with chronic stable heart failure prospectively. MATERIALS AND METHODS: Interventional, open label, prospective, single centered study conducted in the Out patient Department of Cardiology, Tirunelveli Medical College Hospital and 50 patients attending cardiology OPD receiving chronic heart failure therapy. End points noted were improvement in ejection fraction and improvement in left ventricular function. RESULTS: After treatment with Ivabradine, there were no patients with severe LV dysfunction at the end of 1 and 3 months when compared with 5 patients at the baseline. After treatment with study drug patients with moderate LV dysfunction was reduced to 20 at the end of 1 month and 6 patients at the end of 3 months when compared with 35 patients at the baseline. After treatment with study drug the improvement in ejection fraction% was (45.48±5.03) (p<0.001) at the end of 1month and (49.08±4.17) (p<0.001) 3 months compared with the baseline (41.36±6.23). CONCLUSION: We conclude that Ivabradine is safe and effective in treating patients with chronic stable ischemic heart disease.

Keywords: Chronic stable heart failure, Ivabradine, left ventricular function, Ejection fraction.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More